APOD and cancer: In high-risk patients, APOD, OLR1, STC2, and DKK1 were found to be overexpressed, with APOD showing tumor-suppressive effects in certain cancers, while OLR1, STC2, and DKK1 are known to promote tumor growth and immune suppression.